Which family members are considered high risk and should be tested for Factor V Leiden?

High-Risk Family Members Requiring Factor V Leiden Testing

Siblings of individuals who are homozygous for Factor V Leiden or compound heterozygotes (Factor V Leiden + prothrombin G20210A) should be tested, as should first-degree relatives of individuals with VTE who are known Factor V Leiden carriers, particularly when these relatives are pregnant, contemplating pregnancy, or considering oral contraceptive use. 1

Specific High-Risk Family Members Who Should Be Tested

Highest Priority - Testing Recommended:

1. Siblings of homozygous or compound heterozygous carriers

• Siblings of individuals known to be homozygous for Factor V Leiden 1
• Siblings of individuals who are double heterozygotes (Factor V Leiden + prothrombin G20210A) 1
• These individuals face substantially elevated risk, with homozygous Factor V Leiden conferring an 18-fold increased VTE risk compared to non-carriers 2

2. First-degree relatives in specific clinical contexts

• Asymptomatic pregnant individuals or those contemplating pregnancy who have a first-degree relative with VTE history and known homozygous Factor V Leiden or double heterozygosity 1
• Asymptomatic individuals contemplating estrogen use (oral contraceptives or hormone replacement therapy) with a first-degree relative who has VTE history and is homozygous Factor V Leiden or double heterozygous 1

Secondary Priority - Testing May Be Considered:

3. Relatives of known Factor V Leiden carriers (any genotype)

• First-degree relatives of individuals known to have Factor V Leiden, particularly when knowledge would influence pregnancy management or oral contraceptive decision-making 3
• The 2001 ACMG guidelines note this as a "may be considered" indication, recognizing that carrier status knowledge can guide clinical decisions 3

4. Relatives of young VTE patients

• Relatives of individuals with venous thrombosis under age 50 3
• This recommendation stems from the familial clustering of thrombotic risk

Key Clinical Context and Nuances

Why These Specific Relatives?

The rationale differs based on genotype severity:

• Homozygous carriers have annual VTE incidence of approximately 180 per 10,000 (1.8% per year), compared to 10 per 10,000 in the general population 4
• Heterozygous carriers have more modest risk (annual incidence 0.67%), with relative risk of 6.6 compared to non-carriers in family studies 5
• Compound heterozygotes face 59% recurrence rates and high unprovoked event rates 6

When Testing Provides Clinical Utility:

Testing is most valuable when results will actually change management:

• During pregnancy: Knowledge allows for appropriate thromboprophylaxis decisions 1
• Before oral contraceptive use: Female relatives of Factor V Leiden carriers benefit from screening, as the combination increases VTE risk 30-fold 3. Cost-effectiveness analysis supports screening with counseling and prophylaxis during high-risk periods 7
• During high-risk periods: Screening identifies carriers who benefit from thromboprophylaxis during surgery, prolonged immobilization, or extended travel 1

Important Caveats:

Do NOT test:

• Asymptomatic minors, as VTE rarely occurs before young adulthood even in homozygous state 1
• Newborns or fetuses (prenatal testing not indicated) 3, 1
• Random population screening is not recommended 3

The low penetrance matters: Even in heterozygous carriers from affected families, the annual VTE incidence is only 0.34-0.67% 5, 8, which is considerably lower than the 1.7% seen in highly selected thrombophilic families. This means continuous anticoagulation is not justified for asymptomatic carriers 5, but targeted prophylaxis during high-risk periods is appropriate.

Practical Algorithm:

1. Identify the proband's genotype (heterozygous, homozygous, or compound heterozygous)
2. If homozygous or compound heterozygous: Test all siblings
3. If heterozygous with VTE <50 years: Consider testing first-degree relatives, especially:
   • Women of reproductive age
   • Those considering oral contraceptives
   • Those who are pregnant or planning pregnancy
4. Provide genetic counseling about implications, including potential insurance discrimination concerns 3

The evidence strongly supports that testing asymptomatic relatives is most valuable when it enables risk-period prophylaxis rather than continuous anticoagulation, given the unfavorable benefit-harm ratio of long-term anticoagulation in low-penetrance carriers 4, 5.